Antihyperlipidemic Drugs Market by Drug Class (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, and Combination): Global Opportunity Analysis and Industry Forecast, 20192026
- Published Date: 2020-10-18
- Report ID: 3862
- Pages: 184
-
Format:
The global antihyperlipidemic drugs market accounted for $9,456 million in 2018, and is expected to reach $16,864 million by 2026, registering a CAGR of 7.5% from 2019 to 2026.
Lipids are defined as the organic compounds that are fatty acids. These fatty acids are essential and serve as building blocks of the cellular membranes in the living organisms. However, surge in level of lipids in the blood leads to their deposition in the arteries. This deposition of the lipids in the arteries leads to blockage, which in turn increases the risk of heart attacks. Therefore, the condition requires early detection and treatment. The treatment of hyperlipidemia is carried out using antihyperlipidemic drugs. Some of the antihyperlipidemic drugs available in the market include statins, bile acid sequestrants, cholesterol absorption inhibitors, and others.
The factors that contribute for the growth of the market include surge in sedentary lifestyle. Furthermore, rise in incidence of disorders related to distributed cholesterol levels in the blood also contributes to the growth of the antihyperlipidemic drugs market. Moreover, surge in awareness regarding complications related with hyperlipidemia is another major factor that fuels the growth of the market. However, high cost of the treatment hinders the market growth. Conversely, growth opportunities exhibited by emerging economies is expected to offer lucrative opportunities for the market growth during the forecast period.
The antihyperlipidemic drugs market size is studied based on segments, drug class and region, to provide a detailed assessment of the market. Based on drug class, the market is divided into statins, pcsk9 inhibitors, bile acid sequestrants, cholesterol absorption inhibitors, fibric acid derivatives, and combination. Based on region, the antihyperlipidemic drugs market size is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
This report entails a detailed quantitative analysis along with the current global antihyperlipidemic market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
The market size and estimations are based on a comprehensive analysis of key developments in the industry.
A qualitative analysis based on innovative products facilitates strategic business planning.
The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
By Drug Class
o Statins
o PCSK9 Inhibitors
o Bile Acid Sequestrants
o Cholesterol Absorption Inhibitors
o Fibric Acid Derivatives
o Combination
o Symptoms Check
By Region
o North America
U.S.
Canada
Mexico
o Europe
Germany
France
UK
Italy
Spain
Rest of Europe
o Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
o LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
List of key players profiled in the report:
Boehringer Ingelheim GmbH
Merck KGaA
Johnson and Johnson
Bayer AG
Pfizer, Inc.
Takeda Pharmaceutical Co., Ltd.
AstraZeneca plc,
Chapter 1: Introduction
1.1. Report Description
1.2. Key Market Segments
1.2.1. List of Key Players Profiled In The Report
1.3. Research Methodology
1.3.1. Primary Research
1.3.2. Secondary Research
1.3.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Top Player Positioning
3.2.1. Top Investment Pockets
3.3. Key Forces Shaping Antihyperlipidemic Industry/Market
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Presence of Guidelines Recommending The Use of Statins
3.4.1.2. Surge In Healthcare Expenditure Worldwide
3.4.1.3. Rise In Prevalence of Hyperlipidemia Across The Globe
3.4.2. Restraint
3.4.2.1. Upcoming Patent Expirations of Drugs
3.4.3. Opportunity
3.4.3.1. High Growth Potential In Developing Economies
3.4.4. Impact Analyses
Chapter 4: Antihyperlipidemic Drugs Market, By Drug Class
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Statins
4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis By Country
4.3. Bile Acid Sequestrants
4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis By Country
4.4. Cholesterol Absorption Inhibitors
4.4.1. Key Market Trends, Growth Factors, And Opportunities
4.4.2. Market Size And Forecast, By Region
4.4.3. Market Analysis By Country
4.5. Fibric Acid Derivatives
4.5.1. Key Market Trends, Growth Factors, And Opportunities
4.5.2. Market Size And Forecast, By Region
4.5.3. Market Analysis By Country
4.6. Pcsk9 Inhibitors
4.6.1. Key Market Trends, Growth Factors, And Opportunities
4.6.2. Market Size And Forecast, By Region
4.6.3. Market Analysis By Country
4.7. Combination
4.7.1. Key Market Trends, Growth Factors, And Opportunities
4.7.2. Market Size And Forecast, By Region
4.7.3. Market Analysis By Country
4.8. Others
4.8.1. Key Market Trends, Growth Factors, And Opportunities
4.8.2. Market Size And Forecast, By Region
4.8.3. Market Analysis By Country
Chapter 5: Antihyperlipidemic Drugs Market, By Region
5.1. Overview
5.1.1. Market Size And Forecast
5.2. North America
5.2.1. Key Market Trends And Opportunities
5.2.2. Market Analysis, By Country
5.2.2.1. U.S.
5.2.2.1.1. U.S. Market Size And Forecast, By Drug Class
5.2.2.2. Canada
5.2.2.2.1. Canada Market Size And Forecast, By Drug Class
5.2.2.3. Mexico
5.2.2.3.1. Mexico Market Size And Forecast, By Drug Class
5.2.3. North America Market Size And Forecast, By Drug Class
5.3. Europe
5.3.1. Key Market Trends And Opportunities
5.3.2. Market Analysis, By Country
5.3.2.1. Germany
5.3.2.1.1. Germany Market Size And Forecast, By Drug Class
5.3.2.2. France
5.3.2.2.1. France Market Size And Forecast, By Drug Class
5.3.2.3. Uk
5.3.2.3.1. Uk Market Size And Forecast, By Drug Class
5.3.2.4. Italy
5.3.2.4.1. Italy Market Size And Forecast, By Drug Class
5.3.2.5. Rest of Europe
5.3.2.5.1. Rest of Europe Market Size And Forecast, By Drug Class
5.3.3. Europe Market Size And Forecast, By Drug Class
5.4. Asia-Pacific
5.4.1. Key Market Trends And Opportunities
5.4.2. Market Analysis, By Country
5.4.2.1. Japan
5.4.2.1.1. Japan Market Size And Forecast, By Drug Class
5.4.2.2. China
5.4.2.2.1. China Market Size And Forecast, By Drug Class
5.4.2.3. India
5.4.2.3.1. India Market Size And Forecast, By Drug Class
5.4.2.4. Rest of Asia-Pacific
5.4.2.4.1. Rest of Asia-Pacific Market Size And Forecast, By Drug Class
5.4.3. Asia-Pacific Market Size And Forecast, By Drug Class
5.5. Lamea
5.5.1. Key Market Trends And Opportunities
5.5.2. Market Analysis, By Country
5.5.2.1. Brazil
5.5.2.1.1. Brazil Market Size And Forecast, By Drug Class
5.5.2.2. South Africa
5.5.2.2.1. South Africa Market Size And Forecast, By Drug Class
5.5.2.3. Saudi Arabia
5.5.2.3.1. Saudi Arabia Market Size And Forecast, By Drug Class
5.5.2.4. Rest of Lamea
5.5.2.4.1. Rest of Lamea Market Size And Forecast, By Drug Class
5.5.3. Lamea Market Size And Forecast, By Drug Class
Chapter 6: Company Profiles
6.1. Abbvie Inc.
6.1.1. Company Overview
6.1.2. Company Snapshot
6.1.3. Operating Business Segments
6.1.4. Product Portfolio
6.1.5. Business Performance
6.2. Amgen Inc.
6.2.1. Company Overview
6.2.2. Company Snapshot
6.2.3. Operating Business Segments
6.2.4. Product Portfolio
6.2.5. Business Performance
6.2.6. Key Strategic Moves And Developments
6.3. Astrazeneca Plc
6.3.1. Company Overview
6.3.2. Company Snapshot
6.3.3. Operating Business Segments
6.3.4. Product Portfolio
6.3.5. Business Performance
6.4. Bristol-Myers Squibb Company
6.4.1. Company Overview
6.4.2. Company Snapshot
6.4.3. Operating Business Segments
6.4.4. Product Portfolio
6.4.5. Business Performance
6.5. Daiichi Sankyo Company, Limited
6.5.1. Company Overview
6.5.2. Operating Business Segments
6.5.3. Product Portfolio
6.5.4. Business Performance
6.6. Dr. ReddyS Laboratories Ltd
6.6.1. Company Overview
6.6.2. Company Snapshot
6.6.3. Operating Business Segments
6.6.4. Product Portfolio
6.6.5. Business Performance
6.7. Merck & Co., Inc
6.7.1. Company Overview
6.7.2. Company Snapshot
6.7.3. Operating Business Segments
6.7.4. Product Portfolio
6.7.5. Business Performance
6.8. Mylan N.V
6.8.1. Company Overview
6.8.2. Company Snapshot
6.8.3. Operating Business Segments
6.8.4. Product Portfolio
6.8.5. Business Performance
6.9. Pfizer Inc.
6.9.1. Company Overview
6.9.2. Company Snapshot
6.9.3. Operating Business Segments
6.9.4. Product Portfolio
6.9.5. Business Performance
6.10. Sanofi S.A.
6.10.1. Company Overview
6.10.2. Operating Business Segments
6.10.3. Product Portfolio
6.10.4. Business Performance
6.10.5. Key Strategic Moves And Developments
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
